All In MedTech

FDA Clearance Tracker · P210034-S001

Agili-C

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P210034-S001
Device name
Agili-C
Applicant location
Andover, MA
Received
Dec 11, 2025
Decided
Jun 4, 2026
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P210034

Device type

Device class
Class III

Every decision under product code QRU

FDA's approval statement

As written in FDA's record.

Approval for updated package labeling that incorporates the clinical results from the required postapproval study.

Source documents

Other decisions for Smith and Nephew, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.